Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX2B8E
|
|||
| Drug Name |
TG4010
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2/3 | [1] | |
| Company |
Transgene; Bristol-Myers Squibb
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01383148) Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.